semaglutide rebound drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons can you withdraw from semaglutide

Wegovy (semaglutide) is a prescription injection approved to help with weight loss and reduce the risk of serious cardiovascular issues

Nagoya J Med Sci

Clinical trials demonstrate: Weeks 14 : Minimal weight loss as your body adjusts Months 23 : More noticeable weight reduction as dose escalation continues Months 46 : Steady, consistent weight loss Peak effect : Maximum weight loss typically occurs at 6068 weeks of continuous treatment [15] According to FDA-approved labeling, patients on Wegovy (2.4 mg weekly) lost an average of 15% of their body weight over 68 weeks in clinical trials (STEP 1)

It works by targeting the receptors of glucagon-like peptide-1 (GLP-1), a gut hormone involved in regulating your digestion, appetite, and blood sugar levels

Tirzepatide activates both GLP-1 and GIP receptors, providing dual mechanisms for appetite suppression and metabolic regulation

we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.